Advertisement
YOU ARE HERE: LAT HomeCollectionsViagene Inc
IN THE NEWS

Viagene Inc

FEATURED ARTICLES
BUSINESS
March 21, 1995 | Times Staff and Wire Reports
Chiron, Viagene End Merger Talks: Chiron Corp. and Viagene Inc. ended discussions on a transaction calling for Chiron to acquire Viagene, a San Diego-based bio-pharmaceutical company. Talks between the two companies took place last week, Emeryville, Calif.-based Chiron reported in a Schedule 13D filed with the Securities and Exchange Commission. Chiron said discussions were terminated "without any agreement having been reached."
ARTICLES BY DATE
BUSINESS
March 21, 1995 | Times Staff and Wire Reports
Chiron, Viagene End Merger Talks: Chiron Corp. and Viagene Inc. ended discussions on a transaction calling for Chiron to acquire Viagene, a San Diego-based bio-pharmaceutical company. Talks between the two companies took place last week, Emeryville, Calif.-based Chiron reported in a Schedule 13D filed with the Securities and Exchange Commission. Chiron said discussions were terminated "without any agreement having been reached."
Advertisement
BUSINESS
April 25, 1995 | CHRIS KRAUL, TIMES STAFF WRITER
In another example of the consolidation sweeping the biotechnology industry, Chiron Corp. agreed to acquire the remaining 83% of stock in gene-therapy pioneer Viagene Inc. in a deal valued at about $95 million. Chiron, one of the country's largest maker of vaccines and drugs, and Viagene already collaborate on several products. Chiron, based in Emeryville, Calif., invested $20 million in San Diego-based Viagene in late 1993 to acquire a 17% stake.
BUSINESS
June 25, 1995 | BARBARA MARSH, TIMES STAFF WRITER
The road to riches in biotechnology has never been easy. But now Southern California companies with experimental drugs find it especially hard. Consider ImmunoTherapy Corp., a tiny Tustin company with a vaccine intended to treat cancer. Jeff Lillard, the company's chairman, wants to raise $3.5 million to fund tests in cancer patients. He's talked with more than 100 venture capital firms, investment bankers and big drug firms, but has nothing to show for it.
BUSINESS
July 9, 1995 | BARBARA MARSH, TIMES STAFF WRITER
The road to riches in biotechnology has never been easy. But now Southern California companies with experimental drugs are finding it especially difficult. Consider ImmunoTherapy Corp., a tiny Tustin company with a vaccine intended to combat cancer. Jeff Lillard, the company's chairman, wants to raise $3.5 million to fund tests in cancer patients. He's talked with more than 100 venture capital firms, investment bankers and big drug firms, but Lillard has nothing to show for it.
Los Angeles Times Articles
|